A new primate model for multiple sclerosis in the common marmoset

Immunology Today

Volumn 21, Issue 6, 2000, Pages 290-297

  'T Hart, Bert A ^a,b   Van Meurs, Marjan ^c   Brok, Herbert P M ^a   Massacesi, Luca ^d   Bauer, Jan ^e   Boon, Louis ^f   Bontrop, Ronald E ^a   Laman, Jon D ^c  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF VIENNA   (Austria)

^f Tanox Pharma BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD40 ANTIGEN; GLYCOPROTEIN; GLYCOPROTEIN GP 39; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MU5D12; MYELIN BASIC PROTEIN; PROTEOLIPID PROTEIN; RECOMBINANT BETA INTERFERON; ROLIPRAM; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNITY; B LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DEMYELINATION; HUMAN; IMMUNOHISTOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MARMOSET; MOUSE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; PHYLOGENY; PRIMATE DISEASE; PRIORITY JOURNAL; RAT; REVIEW; RHESUS MONKEY; T LYMPHOCYTE RECEPTOR GENE;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; AUTOIMMUNE DISEASES; CALLITHRIX; CEBIDAE; CERCOPITHECIDAE; CHIMERA; DEMYELINATING DISEASES; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENES, MHC CLASS II; HISTOCOMPATIBILITY ANTIGENS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERFERON-BETA; MULTIPLE SCLEROSIS; RATS; RATS, INBRED LEW; RECEPTORS, ANTIGEN, T-CELL; RODENTIA; ROLIPRAM; SPECIES SPECIFICITY; TWINS;

EID: 0034069934     PISSN: 01675699     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5699(00)01627-3     Document Type: Review

References (35)

1. Lassmann H. Pathology of Multiple Sclerosis. Compston A., Ebers G., Lassmann H., McDonald I., Matthews B., Wekerle H. McAlpine's Multiple Sclerosis. 1998;323-357 Churchill Livingstone.
2. Wekerle H. Immunology of multiple sclerosis. Compston A., Ebers G., Lassmann H., McDonald I., Matthews B., Wekerle H. McAlpine's Multiple Sclerosis. 1998;379-407 Churchill Livingstone.
3. Kalden J.et al. Immunological treatment of autoimmune diseases. Adv. Immunol. 68:1998;333-347.
4. Bontrop R.E.et al. Evolution of major histocompatibility complex polymorphisms and T-cell receptor diversity in primates. Immunol. Rev. 143:1995;33-62.
5. Bontrop R.E.et al. Major histocompatibility complex class II polymorphisms in primates. Immunol. Rev. 167:1999;339-350.
6. Rivers T.M.et al. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 58:1933;39-53.
7. Rose L.M.et al. Remitting-relapsing EAE in nonhuman primates. a valid model of multiple sclerosis Clin. Immunol. Immunopathol. 59:1991;1-15.
8. Stewart M.A.et al. Magnetic resonance imaging of experimental allergic encephalomyelitis in primates. Brain. 114:1991;1069-1096.
9. Van Lambalgen R., Jonker M. Experimental allergic encephalomyelitis in rhesus monkeys: I. Immunological parameters in EAE resistant and susceptible rhesus monkeys. Clin. Exp. Immunol. 67:1987;100-107.
10. Meinl E.et al. Activation of a myelin basic protein-specific human T cell clone by antigen-presenting cells from rhesus monkeys. Int. Immunol. 7:1995;1489-1495.
11. Massacesi L.et al. Experimental allergic encephalomyelitis in cynomolgus monkeys. Quantitation of T cell responses in peripheral blood. J. Clin. Invest. 90:1992;399-404.
12. Shaw C.-M.et al. Chronic remitting-relapsing experimental allergic encephalomyelitis induced in monkeys with homologous myelin basic protein. Ann. Neurol. 24:1988;738-748.
13. Van Lambalgen R., Jonker M. Experimental allergic encephalomyelitis in rhesus monkeys: II. Treatment of EAE with anti-T lymphocyte subset monoclonal antibodies. Clin. Exp. Immunol. 67:1987;305-312.
14. Meinl E.et al. Encephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaques. Am. J. Pathol. 150:1997;445-453.
15. Slierendregt B.L.et al. Identification of an Mhc-DPB1 allele involved in the susceptibility to experimental autoimmune encephalomyelitis in rhesus macaques. Int. Immunol. 7:1995;1671-1679.
16. Tuohy V.K.et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev. 164:1998;93-100.
17. Massacesi L.et al. Actively and passively induced experimental autoimmune encephalomyelitis in common marmosets. a new model for multiple sclerosis Ann. Neurol. 37:1995;519-530.
18. Antunes S.G.et al. The common marmoset. a new world primate species with limited Mhc class II variability Proc. Natl. Acad. Sci. U. S. A. 95:1998;11745-11750.
19. Uccelli A.et al. Characterization of the TCRB chain repertoire in the New World monkey Callithrix jacchus. J. Immunol. 158:1997;1201-1207.
20. Genain C.P., Hauser S.L. Creation of a model for multiple sclerosis in Callithrix jacchus marmosets. J. Mol. Med. 75:1997;187-197.
21. Genain C.P.et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J. Clin. Invest. 96:1995;2966-2974.
22. 'T Hart B.A.et al. Histological characterization of magnetic resonance imaging-detectable brain white matter lesions in a primate model of multiple sclerosis. Am. J. Pathol. 153:1998;649-663.
23. Brok H.P.M.et al. Myelin/oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis in common marmosets. the encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic MHC class II molecule J. Immunol. 2000;. conditionally accepted.
24. Laman J.D.et al. Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus). J. Neuroimmunol. 86:1998;30-45.
25. Gerritse K.et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 93:1996;2499-2504.
26. Laman J.D.et al. CD40 in clinical inflammation. from multiple sclerosis to atherosclerosis Dev. Immunol. 6:1998;215-222.
27. Howard L.M.et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. 103:1999;281-290.
28. Genain C.P.et al. Prevention of autoimmune demyelination in nonhuman primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 92:1995;3601-3605.
29. Van der Meide P.H.et al. Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J. Neuroimmunol. 84:1998;14-23.
30. Kerlero de Rosbo N., Ben-Nun A. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. J. Autoimmun. 11:1998;287-299.
31. Genain C.P.et al. Late complications of immune deviation therapy in a nonhuman primate. Science. 274:1996;2054-2057.
32. Genain C.P.et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5:1999;170-175.
33. Raine C.S.et al. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesion. a case for antigen-specific antibody mediation Ann. Neurol. 46:1999;144-160.
34. Kwekkeboom J.et al. Signalling via CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells. Immunol. 79:1993;439-444.
35. McFarland H.et al. Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis. J. Immunol. 162:1999;2384-2390.